)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Santen Pharmaceutical
Santen Pharmaceutical (4536) investor relations material
Santen Pharmaceutical Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary5 Nov, 2026
Executive summary
H1 revenue rose 3.9% YoY to ¥143.3B; core operating profit increased 7.3% to ¥23.9B, while IFRS net profit rose 11.7% to ¥15.5B.
Overseas growth and favorable FX offset Japan weakness; H1 progress was described as in line with the full-year forecast.
Financial highlights
Gross profit rose 7.1% to ¥82.7B and gross margin increased to 57.7% from 56.0%, reflecting a lower COGS ratio from product mix.
IFRS operating profit was ¥19.4B, up 8.4%; net profit attributable to owners was ¥15.4B, up 10.8%.
EBITDA increased 5.0% to ¥28.4B; basic EPS was ¥48.05 versus ¥41.76 a year earlier.
SG&A rose 9.7% to ¥46.6B; R&D expenses declined 1.9% to ¥12.1B.
Outlook and guidance
Full-year forecasts were maintained: revenue ¥311.0B (+6.6%), core operating profit ¥59.0B (+7.0%) and operating profit ¥49.5B (+3.6%).
Net profit forecast is ¥39.5B (+5.2%); net profit attributable to owners is ¥40.0B (+7.0%); basic EPS is ¥127.56 (+11.9%), including the share-buyback impact.
Assumptions include key-product penetration, Q4 pollen dispersion, China recovery and stable supply; core profit also assumes SG&A optimization and absorption of cost inflation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Santen Pharmaceutical
- Overseas growth bets on commercial excellence, core eye-care brands and new launches.4536
Investor update - Patient-led R&D and novel delivery aim to expand the ophthalmology pipeline and future growth.4536R&D Day 2026
- Revenue up 3.3% year-over-year, driven by overseas growth and new product launches.4536Q1 2025
- Revenue up 0.4% YoY, profits down, with share buybacks and new launches supporting outlook.4536Q2 2025
- Flat revenue, lower core profit, higher dividend, and robust international growth.4536Q3 2025
- EPS surpassed JPY 100 as net profit rose 36.1% YoY, with stable outlook despite generic headwinds.4536Q4 2025
- Revenue and profit declined, but guidance, buybacks, and growth initiatives remain robust.4536Q1 2026
- Revenue and profit declined, but guidance and shareholder return initiatives remain intact.4536Q2 2026
- Revenue and profit declined YoY, but full-year guidance and capital efficiency initiatives remain steady.4536Q3 2026
Next Santen Pharmaceutical earnings date
Q3 20275 Feb, 2027
Santen Pharmaceutical
Next Santen Pharmaceutical earnings date
Q3 20275 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)